Nowadays understanding alternative splicing is one of the greatest challenges in biology, because it is a genetic process much more important than thought at the time of its discovery. In this paper, we explain the approach of using the different available databases and software tools to start a large scale investigation of alternative splice forms. To collect information about alternative splicing we investigated known data in the databases using different computational methods. The investigations proceeded from the genomic sequence data to structural protein data. Then, we interpreted those data to find the relationship between alternative splice forms and protein function and structure. We found some interesting features of alternative splicing which are presented here. We discuss the results of one chosen example. They concern the coverage quality of the protein sequence of a known structure, an EST analysis, the validation of splice variants, the determination of the alternative splice type, and finally the link between alternative splicing and disease. Contact: ina.koch@molgen.mpg.de
INTRODUCTION
The story of alternative splicing began when Sambrook (1977) discovered the mosaic structure of genes in the adenovirus. After that, Gilbert (1978) called the noncoding and coding parts of genes introns and exons. Moreover, he introduced the idea that a mechanism enables exons to join in different schemas, giving rise to distinct transcripts. This mechanism was called alternative splicing, which will be abbreviated here by AS.
It was assumed for a long time that AS was an exceptional event and, in most cases, a unique combination for the assembly of exons occurs. In the past years, numerous surveys, especially bioinformatics studies, see Table 1 , revolutionized the paradigm 'one gene gives rise to one protein'. The estimated frequency of AS in human genes increased dramatically from 5% (Sharp, 1994) to 59% (Consortium, 2001) . AS is now known as the rule and not the exception. Moreover, AS was found to occur in many eukaryotic species with similar frequency (Brett et al., 2002) . These facts suggest the strong biological significance of AS.
AS represents one of the major events that lead to protein diversity. It is in fact so powerful that it can generate more transcripts from a single gene than the number of genes in the entire human genome (<32 000 (Consortium, 2001) ). For example, the Drosophila gene encoding the Down syndrome cell adhesion molecule dscam is a source of huge diversity. This axon guidance receptor plays a key role during development, especially for migration and connection of neurons. The dscam premRNA can give rise to more than 38,000 various mRNA isoforms. Each of them has the ability to form special interactions directing the growing axon to its proper location (Graveley, 2001) . As a matter of fact, AS plays a fundamental role in protein specificity. A still open question is the regulation of AS. Physiological processes need a strong and fine regulation at both time point and tissue type level. If the expression of a transcript occurs at a false time point or in the wrong tissue this can lead to major diseases, such as Alzheimer's or cancer.
The majority of the developed bioinformatics studies were interested in the discovery of AS variants. However, in order to have a full understanding of the consequences of AS, it is important to go further into the proteome level. It is necessary to link the mRNA variants with their protein form that has either a new, or an identical, or even non function. Thus, the following two questions arise: How is it possible to assess the function of each splice variant? How does AS affect the structure of the variant?
Investigating AS data, Lopez (1998) In the first case the loss or addition of a domain will instinctively be associated with the loss or gain of the function linked to this domain. In the second case, however, there exists neither a study nor a model about the consequences for the structure and thus for the function. The aim of our study was to gain some clues that will enable us to answer this second question. We focused on AS forms where only a part of an INTERPRO domain (Apweiler and the Interpro Consortium, 2000) is concerned with AS.
Two papers which resolved the structures of different isoforms of a protein produced by AS (Oakley et al., 2001; Peneff et al., 2001 ) encouraged us to start a detailed and exhaustive analysis to make suggestions for resolving further interesting examples.
We analyzed in silico known proteins for which a maximum of information could be accumulated. In this paper we describe the computational methods we applied to conduct such analyses in a standard and efficient manner. An overview of the methods is given in Figure 1 . As results, we discuss one interesting example in detailthe beta-glucuronidase, see Figure 2 .
The ultimate goal of this study is to link structure and function in the particular case of AS variants. (Bairoch and Apweiler, 2000) is known as the most reliable public database and provides a great source of information and cross references. We searched for human proteins, which exhibit at least one AS variant and one resolved structure using a simple SRS6 search (Zdobnov et al., 2002) in SWISS-PROT with the keywords VARSPLIC, HUMAN, and PDB. Moreover, an automated search retrieved all proteins from this set for which the AS region covers less than an entire INTERPRO domain. We extended this set with the new annotations in SWISS-PROT and checked them for AS forms and availability of structural information.
METHODS

Determination of the protein set SWISS-PROT
Data collection
Starting with the accession numbers of the proteins we collected the information contained in the respective SWISS-PROT files. More precisely, we were interested in (i) the protein sequence, (ii) the protein sequences of the variants, (iii) the domain structure, (iv) the cross references to the EMBL database (Stoesser et al., 2002) , the PDB structure (Berman et al., 2000) , the OMIM database (Hamosh et al., 2002), and (v) 
Structure coverage quality
To be able to use the available structural data in the particular case of our splice variants, the published structure had to cover at least the AS region and ideally most of the protein length. Indeed, only complete coverage can give an accurate representation of the 3D-structure which takes into account all kinds of interactions between amino acids. This condition was checked with a multiple alignment of the sequence of the SWISS-PROT isoform, the sequences of all variants, and the sequences used during the structure resolution. We did the multiple alignments using ClustalW (Thompson et al., 1994) or Dialign (Morgenstern et al., 1998) . The alignments were viewed and edited using Seqlab from the GCG package (Womble, 2000) .
EST analysis
This part of the study aims at providing information concerning tissue and time specificity of the AS variants. We need this data not only to increase our knowledge about each variant, but also to experimentally be able to access each variant within the human organism. ESTs, or expressed sequence tags, are derived from fully processed mRNAs, i.e. mRNAs that are already spliced, polyadenylated, and possess a 5 cap. They are sequenced in a high-throughput manner. ESTs provide a huge quantity of information concerning gene expression in many tissues and cell types at different developmental or tumoral states.
Most of the bioinformatics studies interested in AS use the data issued from EST libraries to detect AS variants. But, the main problem is the poor sequencing quality of the ESTs due to their high rate of production. Therefore, we cautiously checked the alignment of the ESTs to the genomic sequence. In the present study we used the ESTs clustered by GeneNest . In GeneNest, each cluster which should represent a gene is composed of many contigs, which are ideally the counterparts of the mRNA isoforms. A consensus sequence, which is characteristic for each contig, is created from the set of ESTs and mRNAs that form this contig. GeneNest provides information about the library the EST is issued from, i.e. the tissue type, the tumoral or developmental status. We performed a BLAST search (Altschul et al., 1990) with our protein sequence against the GeneNest database of consensus sequences.
Validation of AS variants and determination of AS type
Because the exact processing of AS is not yet fully understood, the discovery of novel splice variants for a given gene using computational methods is a difficult task. Therefore, most of the methods developed to perform this analysis use EST data. structure: 1bhg beta _ glucoronidase (P08236) 1 1 651 long isoform 600 short isoform Fig. 2 . From top to bottom, these are schematic representations of the exon structure, the long isoform, the short isoform, and the sequence of the beta-glucuronidase structure (1bhg). The domain affected by the AS event is colored yellow.
AS prediction is not an ab initio prediction, but rather a careful observation of expression patterns. An alignment with the genomic sequence affords the discovery of novel splicing patterns. First, we looked into the SpliceNest database (Coward et al., 2002) of probable AS variants. The probable AS sites are highlighted based on an alignment of GeneNest contigs with the human genome draft sequence using sim4 (Florea et al., 1998) . However, not all information available in the EMBL database is contained in UNIGENE (Schuler, 1997 ) on which GeneNest is based. In order to be able to argue with a maximum of data at hand, we aligned all sequences provided by the EMBL cross references in SWISS-PROT (ESTs, cDNAs, mRNAs, and gene sequences) with the human genome using sim4.
Additionally, to be able to jump from genomic coordinates to mRNA or protein ones, we aligned in each case one mRNA with the main isoform of the protein using Wise2 (Birney and Durbin, 1997) .
In summary, we did the following alignments:
• protein, variants, sequences of structures
• mRNAs, cDNAs, genome
The comparison of the alignments of mRNAs and ESTs to the genome sequence enabled us to find out which type of AS occurs.
There are various types of AS:
1. alternative initiation: the N-terminus part of the protein differs because of the use of an alternative 5 exon 2. alternative termination: the C-terminus part of the protein differs due to a frameshift 3. exon extension (5 or 3 ): an exon is extended, either in 5 or in 3 , because of the use of another splice site that does normally not give rise to a frameshift 4. exon truncation (5 or 3 ): similar case to exon extension 5. cryptic exon/exon skipping: recognition of new splice sites (5 and 3 ), or none recognition of 'usual' ones
Link to disease
Splicing defects are estimated to account for about 15% of disease causing mutation in humans. The vast majority of known genetic lesions that affect splicing are point mutations within the 3 and the 5 splice site (Krawczak et al., 1990) , (Nakai and Sakamoto, 1994) . In addition, splicing regulation errors can also cause diseases. Thus, mRNA splicing is involved in a great number of pathologies of many different types, e.g. in neurological diseases like Alzheimer's disease (A4 amyloid protein), or in cancers (p73, mdm2), in myopathy (dystrophin) . . . Therefore, it is of great interest to point out whether there is a link between a particular variant and a pathology.
In the case of variants causing cancer, the knowledge about the pro-or anti-apoptotic function of different variants could allow for the design of innovative approaches to chemotherapy. Those could consist of modifying AS pathways (Mercante and Kole, 2002) thus inhibiting the overexpression of anti-apoptotic forms.
One way to link disease and AS is to go through the literature. Alternatively, we would need to analyse for each pathology a set of tissues, and compare them with normal ones for each mRNA. This topic will not be considered here.
Secondary structure prediction
We wanted to get an impression of possible changes of the protein conformation caused by AS. Therefore we performed a secondary structure prediction of the SWISS-PROT sequences and the various isoforms using PHD (Rost, 1996) and Jpred (Cuff et al., 1998) . We used two prediction programs especially for cases where the known structure does not cover the complete AS region. For verification we predicted also the secondary structure for the PDB sequences and compared the results with the known PDB secondary structures. We added the predicted secondary structures to the previously mentioned alignment of the protein, variants, and PDB sequences.
Secondary structure prediction is a fast method to get primary assumptions concerning possible changes in the protein fold. One must be careful in using secondary structure prediction methods because these methods are based on great approximations and could fail in the prediction of beta-sheet structures.
RESULTS AND DISCUSSION
Set of proteins
We found 113 human proteins present in SWISS-PROT that possess AS variants and at least one known structure. According to SWISS-PROT annotation, 60 proteins (53%) exhibit only a part of a domain that is affected by AS. They constitute the following search set. 27 (24%) are affected by AS in a whole domain. 14 (12%) proteins are present in both sets, i.e. they both have variants either with only a part or with a whole domain affected by AS. In some cases of multiple domains, we even found partly and completely affected domains within a single variant. In 40 (35%) proteins the AS region covers no described domain. They are not in any of the two sets.
The 60 proteins are sorted according to their length, cellular localisation, number of alternatively spliced variants, function, and AS type. The length distribution of our set is very similar to the statistics on the length of the proteins present in the SWISS-PROT database.
The set studied here shows a good repartition of the proteins among the different cellular compartments, see Figure 3 . The location of the proteins breaks down as follows: 35% nucleus, 29% cytoplasm, 19% extracellular matrix, 13% membrane, and 4% mitochondrium.
It is worth noting that certain proteins can have many cellular localisations, often both nuclear and cytoplasmic. In two cases we found in the literature that different variants have exclusively different cellular localisations. For example, the retinoic acid receptor beta has two isoforms located in the nucleus (beta-1 and beta-2), and one isoform located in the cytoplasm (beta-4).
On average, each protein from our set has 3.6 alternatively spliced variants according to SWISS-PROT annotations. From 9263 human proteins of SWISS-PROT 1167 had annotated splice variants, i.e. less than 13%. The number of genes affected by AS is evaluated to be greater than 59% (Consortium, 2001) . Therefore, there is no doubt that the number of AS annotations will increase drastically, and that also this average number of isoforms is in fact a minimum.
We analysed the repartition of the functions of the proteins, see Figure 4 . It was noticeable that there are many proteins involved in signal transduction or gene expression regulation (46%). Such events have indeed to be subtly regulated. AS is a great and economic opportunity for the cell to produce slightly different proteins able to interact with various proteins, or play diverse roles without having many genes coding for them.
AS plays also a fundamental role in the diversity needed in the neuronal system. The other side of this diversity is that AS can also lead to many neurological disorders, as reviewed in (Dredge et al., 2001 ). In our case, only two proteins are exclusively involved in the neuronal system. But other proteins such as the numerous transcription regulators mentioned above or signal transduction actors may play important roles in neurological functions.
Another vital function for the organism that needs much variety is the immune system. The organism has to adapt its response to the aggressor. Proteins involved in immunity represent 11% of our set.
Last but not least, cell death regulation is a critical function in the cell. The main actors in the apoptosis are the members of the p53 family (p53, p63, p73) , and other proteins that can act as tumour suppressors or help tumour progression. They compose 15% of our set. Interestingly, those proteins are often linked to cancers.
The remaining 25% of our set could not be integrated into one of the previous function types.
The results obtained for one example issued from our set, the beta-glucuronidase (SWISS-PROT accession number: P08236), are discussed beneath. Beta-glucuronidase, see Figure 2 , is a 651 amino acid long cytoplasmic protein. The bacterial homologue of beta-glucuronidase is well known to biologists due to its wide use in molecular biology as a reporter gene. The physiological function of beta-glucuronidase in human cells is the degradation of dermatan and keratan sulfates.
Structure analysis
To address the relationship between protein structure and function, it was important for us to have a good structure coverage of the AS region. Among the 60 proteins composing our set, only 34 (i.e. 57%) possess structural information of good quality. In our case, this means experimentally proven data which cover the part of the protein of interest for us.
There is almost always at least a part of a secondary structure (i.e. helix, or beta sheet) that is removed, inserted, or substituted. This could indicate that AS leads to necessary structural changes which eventually give rise to a refolding of the domain or even of the entire protein, causing functional changes.
Interestingly, first results of our secondary structure prediction show that in most cases the secondary structure of isoforms do not change significantly. In order to visualize those changes and possible refolding, the AS variants would be interesting targets for structure determination.
The X-ray structure of the beta-glucuronidase (1bhg, resolution 2.6Å, (Jain et al., 1996) ), see Figure 5 , encompasses the complete protein length (22-633) and thus the entire AS region. The removed domain in the short isoform is colored blue in Figure 5 . It is made of beta sheets in the main isoform. The green and orange colored atoms in the spacefill model represent the ligands, N-acetyl-D-glucosamine and alpha-D-mannose, respectively. A part of the secondary structure elements Fig. 5 . Structure of the long isoform of beta-glucuronidase (1bhg) at 2.6Åresolution. The structure is colored according to the type of secondary structure (yellow for beta sheets, magenta for helices). The two ligands, N-acetyl-D-glucosamine and alpha-D-mannose are colored green and orange, respectively, as spacefill model. The part missing in the short isoform is colored red. The picture was done using SYBYL software (Tripos Inc, 2000) .
is removed due to the AS event. The consequences of this removal of beta sheets on the folding of the protein is difficult to estimate. According to PHD-and Jpredprediction there is no change to the secondary structure. So, the protein fold is preserved in the short isoform, even though four small beta-strands are missing. These strands are located far away from the ligand binding sites. We assume that the function of the protein will not be lost.
An option to estimate the consequences of such an AS event would be to predict the folding that the protein can adopt. But, either one proceeds by homology and risks missing an important refolding or predicts the structure ab initio and loses the amount of information that could be gained from the known structure. Such predictions would not be sufficient enough. So, it is necessary to have resolved structural examples.
To our knowledge, there are until now only two examples where the structure of two isoforms of the same protein issued from AS are published. The first one (Peneff et al., 2001 ) deals with the human pyrophosphorylase. The structures of two AS variants, AGX1 and AGX2 have been solved. AGX2, made of 522 aminoacids, has an insert of 17 residues within a loop compared with AGX1. This change doesn't lead to 3D conformation changes. However, the quaternary structures of AGX1 and AGX2 are different: AGX1 has a dimeric arrangement, whereas AGX2 is exclusively monomeric. This leads to substrate specificity alteration. With GalNac1P as substrate AGX1 is 2-3 times more active. AGX2 is 8 times more active with GlcNac1P. The inserted loop causes oligomeric changes responsible for the specificity shift.
In the second paper (Oakley et al., 2001) , the structures of two isoforms of the mosquito Anopheles dirus glutathione S-transferase have been solved. They differ by a few aminoacids which form an helix or enlarge loops. These aminoacids don't affect the topology of the active site. The substrate inhibition type is altered. In both cases, the availability of the structures of two isoforms of the same protein has led to a better understanding of the function of the protein and its specificity.
EST analysis
This EST analysis was performed in order to gain information about the tissue where the variants are expressed. Whenever possible, we also wanted to check whether the AS variants are linked with a particular time or space specificity within the human organism.
It is difficult to interpret tissue specificity, because EST library coverage is not yet exhaustive. We can be sure that a particular gene is expressed in a particular tissue, if there is no doubt that an EST which represents this gene is issued from this particular tissue. This 'presence' information is what we wanted to gain. It enables us to search the right tissue for the mRNA of the various isoforms.
On the other side, the fact that no EST corresponding to a gene is found in a library doesn't mean that this gene is not expressed in this particular tissue. This part could just be not sequenced, or not publicly released yet.
As explained in the methods, the information relevant for this EST analysis was collected in GeneNest. The output of one GeneNest cluster representative of the betaglucuronidase is shown in Figure 6 . The EST coverage is really good in this case. We have many ESTs that cover in total many times the entire length of the mRNA. In GeneNest, the colors of the boxes to the right of each EST-ID are codes for the library type. Looking at those colored boxes, we see that beta-glucuronidase is expressed in various tissues.
Validation of AS variants and determination of AS type
It is possible to validate one splice variant by aligning the mRNA sequences or the GeneNest contigs with the genome.
The mRNA sequences that we use are mature mRNAs that should not contain any intronic sequence anymore. In addition, GeneNest contigs are based only on ESTs and mRNAs, which are also processed sequences. The alignment highlights, consequently, the exonic parts of the gene. However, errors can occur due to different kinds of experimental factors (Modrek and Lee, 2002) . From the alignment, we are able to detect AS variants, because there are mRNAs (or contigs) that show an obvious deletion or insertion, in comparison to others.
In case of beta-glucuronidase, the short isoform exhibits an exon skipping when compared to the long isoform. The exon 6 is skipped in the short isoform.
The AS type was analysed in the whole set, which gives the following distribution, see Figure 7 . There are 40% of exon skipping or use of cryptic exon, 23% of exon truncation events, 6% of exon extension cases, 18% of alternative initiation, and 13% of exon termination cases.
Exon skipping or the use of a cryptic exon, which are actually the same events but observed from different points of view, are the most frequent types of AS in our set. There are only a few cases where the open reading frame is shifted, which corresponds to the results from Modrek et al. (2001) .
CONCLUSION
In summary, AS is an event of greatest importance. On one hand, it gives rise to the diversity that an organism needs to function properly. On the other hand, AS is involved in a great number of diseases.
In order to achieve a full understanding of the consequences of AS in protein function, it is necessary to go into the proteome level and to have data concerning the structure of the different variants. The 3D-structure of a protein actually determines its interactions with other proteins. Ultimately, those protein networks are responsible for all possible functions in an organism. This paper presents a strategy that can be used to infer the function of known AS forms using available databases and computational tools. By means of one example, we demonstrated how to find, to validate, and to analyse AS data. We discussed experimental and theoretical limitations of AS investigations.
AS events concerning only a part of a protein domain occur very often in a broad range of cell compartments. Although in most cases, the affected part of the protein is so large that a refolding could be assumed, the results of secondary structure prediction lead to the opposite statement. Further investigations should focus on this contradiction between both assumptions.
